Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Abstract:

:Acyclovir (aciclovir) is a nucleoside antiviral drug with antiviral activity in vitro against members of the herpes group of DNA viruses. As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of acyclovir provide significant therapeutic benefit in genital herpes simplex and recurrent orofacial herpes simplex. The effect of acyclovir therapy is maximised by early initiation of treatment, especially in non-primary infection which tends to have a less protracted course than the primary episode. Long term prophylactic oral acyclovir, in patients with frequent episodes of genital herpes simplex, totally suppresses recurrences in the majority of subjects; as with other infections responding to acyclovir, viral latency is not eradicated and pretreatment frequencies of recurrence return after discontinuation of treatment. Caution should accompany the prophylactic use of acyclovir in the general population, due to the theoretical risk of the emergence of viral strains resistant to acyclovir and other agents whose mechanism of action is dependent on viral thymidine kinase. Intravenous acyclovir is the treatment of choice in biopsy-proven herpes simplex encephalitis in adults, and has also been successful in the treatment of disseminated herpes simplex in pregnancy and herpes neonatorium. Intravenous and oral acyclovir protect against dissemination and progression of varicella zoster virus infection, but do not protect against post-herpetic neuralgia. In immunocompromised patients, intravenous, oral and topical acyclovir shorten the clinical course of herpes simplex infections while prophylaxis with oral or intravenous dosage forms suppresses reactivation of infection during the period of drug administration. Ophthalmic application of 3% acyclovir ointment rapidly heals herpetic dendritic corneal ulcers and superficial herpetic keratitis. Thus, despite an inability to eradicate latent virus, acyclovir administered in therapeutic or prophylactic fashion is now the standard antiviral therapy in several manifestations of herpes simplex virus infection, and indeed represents a major advance in this regard. With the exception of varicella zoster virus infections, early optimism concerning the use of the drug in diseases due to other herpes viruses has generally not been supported in clinical investigations.

journal_name

Drugs

journal_title

Drugs

authors

O'Brien JJ,Campoli-Richards DM

doi

10.2165/00003495-198937030-00002

subject

Has Abstract

pub_date

1989-03-01 00:00:00

pages

233-309

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

37

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Use of oral rehydration therapy in acute watery diarrhoea. A practical guide.

    abstract::Various foods and fluids have been used in traditional treatments for diarrhoeal illnesses in infants and children for centuries. During the last 2 decades, however, with the advent of an improved scientific understanding of oral rehydration, effective treatment of dehydrating diarrhoea has been improved, expanded and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141040-00005

    authors: Sack DA

    更新日期:1991-04-01 00:00:00

  • Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.

    abstract::Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197611060-00006

    authors: MacLeod SM,Sellers EM

    更新日期:1976-01-01 00:00:00

  • Tocilizumab: a review of its use in the management of rheumatoid arthritis.

    abstract::Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous tocilizumab 8 mg/kg (and no less than 4.8 mg), in combination with methotrexate, is approved in the EU for the treatment of moderate to severe active rheumatoid arthriti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969050-00007

    authors: Oldfield V,Dhillon S,Plosker GL

    更新日期:2009-01-01 00:00:00

  • Sirolimus use in recipients of expanded criteria donor kidneys.

    abstract::With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868001-00006

    authors: House AA,Nguan CY,Luke PP

    更新日期:2008-01-01 00:00:00

  • Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.

    abstract::Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0541-z

    authors: Blair HA,Keating GM

    更新日期:2016-03-01 00:00:00

  • The diuretic dilemma and the management of mild hypertension.

    abstract::Diuretics are used in first-step antihypertensive monotherapy or in combination with adrenergic-inhibiting agents in the majority of hypertensive patients in the United States. A 30-year experience has demonstrated that blood pressure is lowered to as great or greater a degree with diuretics than when many of the pres...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600314-00007

    authors: Moser M

    更新日期:1986-01-01 00:00:00

  • The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.

    abstract::Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01086-0

    authors: Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

    更新日期:2019-05-01 00:00:00

  • Migalastat: First Global Approval.

    abstract::Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare disorder that results in a deficiency or absen...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0607-y

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Approaches to the Pharmacological Management of Jet Lag.

    abstract::For many years now a treatment mitigating the debilitating effects of jet lag has been sought. Rapid travel across time zones leads, in most people, to temporary symptoms, in particular poor sleep, daytime alertness and poor performance. Mis-timed circadian rhythms are considered to be the main factor underlying jet-l...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0973-8

    authors: Arendt J

    更新日期:2018-09-01 00:00:00

  • Ebastine in context. Introduction.

    abstract::The allergic reaction to a specific antigen is characterised by a series of complex immunological processes consisting of an early specific immune response and a late inflammatory reaction. The release of active substances (principally histamine) from cytoplasmic granules of mast cells and basophils in response to ant...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600521-00003

    authors: Buendia E

    更新日期:1996-01-01 00:00:00

  • What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

    abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00002

    authors: Momméja-Marin H,Carbon C

    更新日期:1999-06-01 00:00:00

  • Insulin glulisine: a review of its use in the management of diabetes mellitus.

    abstract::Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. It has similar binding properties, and is associated with a faster onset but similar level of glucose disposal, to regular human insulin (RHI). Insulin gl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969080-00006

    authors: Garnock-Jones KP,Plosker GL

    更新日期:2009-05-29 00:00:00

  • Microbiological evaluation of cefpodoxime proxetil.

    abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199100423-00004

    authors: Wiedemann B,Luhmer E,Zühlsdorf MT

    更新日期:1991-01-01 00:00:00

  • Current use and future potential role of retinoids in dermatology.

    abstract::Since their introduction 15 years ago, retinoids have been increasingly used for topical and systemic treatment of psoriasis and other hyperkeratotic and parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related dermatoses, and also for therapy and/or chemoprevention of skin cancer and other...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753030-00003

    authors: Orfanos CE,Zouboulis CC,Almond-Roesler B,Geilen CC

    更新日期:1997-03-01 00:00:00

  • The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

    abstract::This paper reviews the use of the fluoroquinolone antibiotics in the management of sexually transmitted diseases (STD) in Southeast Asia. Numerous clinical trials performed in the region have shown that the quinolones are highly effective for treating uncomplicated gonorrhoea. Norfloxacin 800 mg, ofloxacin 400 mg, cip...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00019

    authors: Sivayathorn A

    更新日期:1995-01-01 00:00:00

  • Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

    abstract::Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0756-7

    authors: Keating GM

    更新日期:2017-06-01 00:00:00

  • Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.

    abstract::Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil. Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600322-00004

    authors: Greene DA

    更新日期:1986-01-01 00:00:00

  • Prevention of transplant rejection: current treatment guidelines and future developments.

    abstract::In the past 2 decades, progressive improvements in the results of organ transplantation as a therapeutic strategy for patients with end-stage organ disease have been achieved due to greater insight into the immunobiology of graft rejection and better measures for surgical and medical management. It is now known that T...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754040-00003

    authors: Perico N,Remuzzi G

    更新日期:1997-10-01 00:00:00

  • Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

    abstract::Infliximab, the chimeric monoclonal antibody directed against tumour necrosis factor (TNF)-alpha, has profoundly changed therapy for Crohn's disease (CD). However, for ulcerative colitis (UC), before the publication of ACT 1 and ACT 2 (Active Ulcerative Colitis Trials 1 and 2), there were only a few open-label and con...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666160-00002

    authors: Thukral C,Cheifetz A,Peppercorn MA

    更新日期:2006-01-01 00:00:00

  • Assessment of the risk-benefit ratio for antiarrhythmic drug use.

    abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00005

    authors: Campbell RW

    更新日期:1988-11-01 00:00:00

  • Inflammatory bowel disease management. Some thoughts on future drug developments.

    abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753020-00001

    authors: Rhodes J,Thomas G,Evans BK

    更新日期:1997-02-01 00:00:00

  • Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.

    abstract::In a double-blind, parallel-group randomised trial of 3 months' duration, the efficacy of cyclandelate 800 mg twice daily in migraine prophylaxis was compared with that of flunarizine 5mg daily in 40 patients. In comparison with placebo and baseline values, both drugs significantly relieved symptoms of migraine as ass...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700332-00019

    authors: Nappi G,Sandrini G,Savoini G,Cavallini A,de Rysky C,Micieli G

    更新日期:1987-01-01 00:00:00

  • Lung tissue penetration of temocillin.

    abstract::Eight patients about to have the whole or part of a lung resected were given a 2g bolus dose of temocillin. A series of serum samples and a piece of peripheral lung tissue were collected and assayed for temocillin concentration. 30 minutes after drug administration, the mean serum and tissue concentrations were 172 mg...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00031

    authors: Cowan W,Baird A,Sleigh JD,Gray JM,Leiper JM,Lawson DH

    更新日期:1985-01-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Pathophysiology and treatment of hepatitis C.

    abstract::Hepatitis C virus (HCV) infection is associated with a variable disease course and response to therapy. Some infected patients may develop little or no disease for 30 to 40 years, whereas others will develop cirrhosis within 5 to 10 years. Both host and viral factors influence the rate of disease progression. The mana...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600522-00003

    authors: Thomas HC,Booth J,Brown J

    更新日期:1996-01-01 00:00:00

  • Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus.

    abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161140-00001

    authors: Robertson RP

    更新日期:2001-01-01 00:00:00

  • Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

    abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161140-00011

    authors: Keating GM,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.

    abstract::Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01130-z

    authors: Schehlein EM,Robin AL

    更新日期:2019-07-01 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.

    abstract::Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01394-w

    authors: Nunnery SE,Mayer IA

    更新日期:2020-11-01 00:00:00